论文部分内容阅读
目的探讨莫西沙星和阿莫西林克拉维酸钾治疗慢性支气管炎急性发作(AECB)的经济性。方法基于全社会角度,选取AECB门诊患者(≥18岁)为研究对象,构建决策树模型,对莫西沙星和阿莫西林克拉维酸钾治疗AECB进行成本-效果分析。疗效和不良反应数据来源于随机对照试验(RCT)文献,药品成本采用广东省医疗机构药品网上采购系统公布的零售价中位数,不良反应治疗成本通过专家问卷调查获得。结果在基础分析中,莫西沙星组的治疗效果优于阿莫西林克拉维酸钾组,且总成本较低,为优势方案,阿莫西林克拉维酸钾组为劣势方案,增量成果比值(ICER)为-1 900.08元。在敏感性分析中,结果与基础分析基本一致。结论对于AECB的治疗,莫西沙星的经济性优于阿莫西林克拉维酸钾。
Objective To investigate the economy of acute attack of chronic bronchitis (AECB) by moxifloxacin and amoxicillin-clavulanate potassium. Methods AECB outpatients (≥18 years old) were selected as the research object to establish a decision tree model for the cost-effectiveness analysis of AECB for moxifloxacin and amoxicillin-potassium clavulanate in the treatment of AECB. Efficacy and side effects data were collected from randomized controlled trials (RCTs). The cost of medicines was calculated based on the median retail price published by the online pharmacy of Guangdong Medical Institutions. Adverse drug treatment costs were obtained through expert questionnaires. Results In the basic analysis, the treatment effect of moxifloxacin group was superior to that of amoxicillin and clavulanate group, and the total cost was lower, which was the superiority plan. The amoxicillin and clavulanate group was the inferiority plan, and the incremental outcome ratio (ICER) was -1 900.08 yuan. In the sensitivity analysis, the results are basically the same as the basic analysis. Conclusion For the treatment of AECB, moxifloxacin is superior to amoxicillin and clavulanate potassium in economy.